Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 72

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Acute lymphocytic leukaemia

Recruiting

Study on the Safety and Effectiveness of Tafasitamab for Children with Relapsed or Refractory Acute B Lineage Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tafasitamab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Diffuse large B-cell lymphoma

Recruiting

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Busulfan
  • Sponsor:Medical Center - University Of Freiburg

Plasma cell myeloma

Recruiting

Study of Ciltacabtagene Autoleucel and Drug Combination for Treatment of High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Colorectal cancer metastatic

Recruiting

Study of Hyperthermic Intraperitoneal Chemotherapy with Irinotecan and Fluorouracil in Patients with Colorectal Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Uppsala University

Otitis media+1

Recruiting

Study on Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps and Eosinophilic Otitis Media

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Amsterdam UMC Stichting

Small cell lung cancer extensive stage

Recruiting

Study of Ifinatamab Deruxtecan with Atezolizumab and Carboplatin for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Daiichi Sankyo Inc.

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Hepatocellular carcinoma

Recruiting

Study of Fecal Microbiota Transplantation combined with atezolizumab and bevacizumab in patients with unresectable liver cancer who progressed after initial treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico

Colorectal cancer metastatic

Recruiting

Study on Bevacizumab-Based Chemotherapy for Patients with Unresectable Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Breast cancer metastatic+3

Recruiting

Study on the Impact of Exercise and Atorvastatin on Advanced Breast, Ovarian, Prostate, and Kidney Cancer Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Pirkanmaan hyvinvointialue

Pancreatic carcinoma

Recruiting

Study on the Effectiveness of [18F]FAPI-74 PET/CT for Detecting Lymph Node Spread in Patients with Pancreatic Cancer

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:Turku University Hospital

Non-small cell lung cancer

Recruiting

Study of Sacituzumab and Zimberelimab for Patients with Resectable Non-Small Cell Lung Cancer After Surgery Without Complete Disease Clearance

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zimberelimab
  • Sponsor:Fundacion GECP

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.